Novavax (NVAX)

Company Description

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates.


 

COMPANY ADDRESS
9920 Belward Campus Drive
Rockville, Maryland 20850
United States

COMPANY PHONE
240-268-2000

COMPANY WEBSITE



Get BioInvest's perspective on Novavax's CEO


Latest Company News

Novavax Inc (NVAX) Reaches Active Mover List Morgan Research - 9 hours ago Shares of Novavax Inc (NVAX) are moving on volatility today 2.02% or 0.02 from the open. The NASDAQ listed company saw a recent bid of 1.01 and 2349343 shares have traded hands in the session. [...]
Fri, Aug 18, 2017 7:52:00 PM, Continue reading at the source
Why to Keeping Eye on Novavax, Inc. (NVAX), AMC Entertainment Holdings, Inc ... StockNewsJournal - 13 hours ago Novavax, Inc. (NVAX) have shown a high EPS growth of -43.40% in the last 5 years and has earnings decline of -72.80% yoy. [...]
Fri, Aug 18, 2017 3:45:00 PM, Continue reading at the source
Novavax, Inc. (NASDAQ:NVAX) Earns "Neutral" Rating from Chardan Capital ExpressNewsline - Aug 17, 2017 Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Earnings Estimates Revision Screen: Novavax, Inc. (NVAX) - HiTechFacts [...]
Thu, Aug 17, 2017 6:19:00 PM, Continue reading at the source
The Markets Are Undervaluing these stock's: The Gap, Inc. (GPS), Novavax, Inc ... StockNewsJournal - Aug 14, 2017 The Gap, Inc. (NYSE:GPS) market capitalization at present is $9.12B at the rate of $23.15 a share. The firm's price-to-sales ratio was noted 0.59 in contrast with an overall industry average of 2.09. [...]
Mon, Aug 14, 2017 12:22:00 PM, Continue reading at the source
Buy or Sell? What Analysts Recommends: Novavax, Inc. (NVAX), Automatic Data ... StockNewsJournal - Aug 10, 2017 Investors who are keeping close eye on the stock of Novavax, Inc. (NASDAQ:NVAX) established that the company was able to keep return on investment at -59.67 in the trailing twelve month while Reuters data showed that industry's average stands at 1.38 ... Stocks Views And Recommendations: Novavax, Inc. (NVAX), Automatic Data ... - AllStockNews [...]
Thu, Aug 10, 2017 1:07:00 PM, Continue reading at the source
Novavax Reaching Critical Mass? Seeking Alpha - Aug 8, 2017 Novavax (NVAX) is a $290 million market cap company focused on using recombinant nanoparticle vaccine technology to treat a wide range of infectious disease. Novavax Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release) [...]
Tue, Aug 08, 2017 6:45:00 PM, Continue reading at the source
Top Earnings Today - Disney, Novavax, Inc And Priceline Stock Amigobulls - Aug 8, 2017 In today's earnings post we will be covering Walt Disney Co, Novavax Inc and Priceline group. While studios and theme parks are likely to post good numbers for Disney, ESPN numbers and commentary will be the key thing to watch out for. [...]
Tue, Aug 08, 2017 11:06:00 AM, Continue reading at the source
The Single Best Reason to Buy Novavax Stock Now Motley Fool - Aug 1, 2017 Buy the rumor and sell the news doesn't always work out so well. Investors who followed the old adage with Novavax (NASDAQ:NVAX) recently learned that lesson the hard way. Novavax, Inc. (NASDAQ:NVAX) Touching Most Active List Today - ExpressNewsline Analysts Insights on Novavax Inc (NVAX) - ExpertGazette [...]
Tue, Aug 01, 2017 6:56:00 PM, Continue reading at the source
Novavax, Inc.: Buy the Dip? Motley Fool - Jul 27, 2017 The results were so encouraging that the Bill & Melinda Gates Foundation awarded Novavax with a grant worth up to $89 million to support further development of the product. Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages - Newburgh Gazette Novavax, Inc. (NASDAQ:NVAX) Rating Reiterated by Piper Jaffray Companies - TheOlympiaReport [...]
Thu, Jul 27, 2017 2:26:00 PM, Continue reading at the source
Why Novavax, Inc Is Tanking Today Motley Fool - Jul 25, 2017 First, Novavax said that its phase 3 Prepare trial -- which is studying its respiratory syncytial virus candidate, RSV F Vaccine, in infants via maternal immunization -- continues to progress. Novavax CEO: 'We have a vaccine we like' - Washington Business Journal Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and ... - GlobeNewswire (press release) [...]
Tue, Jul 25, 2017 4:18:00 PM, Continue reading at the source